- Biohaven Pharmaceutical (NYSE:BHVN) announces that it has commenced enrollment in the first of its two registrational Phase 3 clinical trials to evaluate the safety and efficacy of orally-dosed rimegepant (BHV-3000) for the acute treatment of migraine.
- Enrollment in the second Phase 3 clinical trial is expected to begin this summer and topline results for both studies will be reported in 1H2018.
- The co-primary endpoints of the studies are freedom from pain at two hours post-dosing and a demonstrated effect on nausea, photophobia or phonophobia.